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Abstract: The benzodiazepine class of drugs are characterised by a readily electrochemically 
reducible azomethine group. A number are also substituted by other electrochemically active nitro, 
N-oxide, and carbonyl groups, making them readily accessible to electrochemical determination. 
Techniques such as polarography, voltammetry, and potentiometry have been employed for 
pharmaceutical and biomedical samples, requiring little sample preparation. This review describes 
current developments in the design and applications of electrochemical-based approaches for the 
determination of the benzodiazepine class of drugs form their introduction in the early 1960s to 
2019. Throughout this period, state-of-the-art electroanalytical techniques have been reported for 
their determination. Polarography was first employed focused on mechanistic investigations. 
Subsequent studies showed the adsorption of many the benzodiazepines at Hg electrodes allowed 
for the highly sensitive technique of adsorptive stripping voltammetry to be employed. The 
development and introduction of other working electrode materials such as carbon led to techniques 
such as voltammetry to become commonly reported, and the modification of these electrodes has 
now become the most commonly employed approach using molecularly imprinting and 
nanotechnology. 
Keywords: benzodiazepine; electrochemistry; voltammetry; polarography; biomedical; forensic; 
analysis; review 
 
1. Introduction 
Since the introduction of chlordiazepoxide hydrochloride (Librium®) in 1960 [1], a large number 
of structurally similar 1,4- and 1,5-benzodiazepine compounds have been developed and have been 
utilised widely as tranquillisers, hypnotics, sedatives, and antidepressants [2], and are presently one 
of the most commonly prescribed class of drugs. They were originally developed by Dr. Leo 
Sternbach in his doctoral degree studies at Jagiellonian University in Krakow, and then further 
explored during his employment in New Jersey, in the USA, with Wallace Pharmaceuticals. The 
company had already developed a GABA receptor-binding compound, meprobamate, which 
demonstrated powerful tranquillising and sedative effects, but which also exhibited dependence and 
abuse potential. Charged with finding a more benign alternative, Sternbach turned to his previous 
doctorial research on benzodiazepines. After exploring, unsuccessfully, over 40 different compounds 
over a period of two years, in 1956, animal testing of a material he named Ro 5–0690 showed definite 
tranquillising effects with no apparent side effects. This compound was later named 
methaminodiazepoxide, and then chlordiazepoxide (Librium®), and was approved for use in 1960. 
Librium® was then followed in 1963 by diazepam (Valium®), and today, there are more than 1000 
benzodiazepines synthesised [3]. Presently, this group of compounds represents one of the most 
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commonly prescribed drugs. Over the period 2009 to 2014, the number of prescriptions dispensed for 
benzodiazepines in the USA increased by 226% to 133.4 million [4]. 
Compared to older sedatives, the application of benzodiazepines was considered to result in less 
side effects, such as toxicity, abuse, physical dependence, and suicide potential. They also exhibit a 
much improved therapeutic ratio, of above 100 compared to only 10 for the older drug classes, such 
as barbiturates [5]. However, more recent studies have shown a growing controversy focused on their 
usage [6]. Prolonged usage has been found to result in increased tolerance, physical dependence, 
increased aggression, and withdrawal symptoms. Overdose can result in symptoms like respiratory 
depression or coma. Reviews [7,8] have highlighted issues with their use with groups, particularly 
the elderly, with increased reports of falls, incidence of hip fractures, and risk of cerebrovascular 
events and deaths. 
Due to their wide pharmaceutical usage and subsequent disposal, concern has also focused on 
other areas affecting the wider population. Reports have highlighted their use in drug-facilitated 
crime (DFC), drug-facilitated sexual assaults (DFSA) [9–11], and their adverse effects on activities 
such as driving [12,13]. Detectable levels have also been recently reported in potable and 
environmental water systems, resulting in possible toxic effects for both humans and aquatic life [14–
17]. Consequently, there is a pressing demand for methods capable of determining trace levels of 
benzodiazepine in a variety of samples, including both environmental and medical. Common 
analytical approaches utilised [18–20] for the determination of benzodiazepines, such as gas 
chromatography and immunoassay [21] and liquid chromatography [22], have recently been 
reviewed. However, to our knowledge, the application of electrochemical-based techniques for their 
determination has not been recently reviewed. 
2. Electrochemical Behaviour of Benzodiazepines 
Benzodiazepines are characterised by a relatively easily reducible azomethine group with a 
number also containing other electrochemically active groups, including nitro, N-oxide and carbonyl 
groups (Appendix A). As a result, many common electrochemical techniques, such as polarography, 
voltammetry, and also potentiometry, have been successfully utilised for their determination. 
Electrochemical-based approaches offer advantages in sensitivity, economy, and flexibility, and have 
been utilised for the successful determination of a range of pharmaceuticals and their metabolites in 
complicated matrices such as blood and urine [23–25], and for forensic analysis [26–29]. 
Electrochemistry has also been shown suitable for analytical quality control of pharmaceutical 
formulations, utilised for quantitative determinations and studies of impurities, and it has also been 
used in biological and mechanistic studies. Utilising techniques such as adsorptive stripping 
voltammetry (AdSV) detection limits in the pM range have been reported (Table 1). 
This review focuses on electrochemically-based approaches for their determination. The subject 
is divided into two main areas, polarographic and voltammetric applications, including details of 
methodology, design, and performance of selected applications. Those utilising liquid 
chromatography with electrochemical detection have been reviewed recently [30]. Discussion is 
focused on research papers published in the past 12 years. Reports made prior to 2006 are 
summarized in Tables 1–3. A number of these earlier investigations have already been reviewed 
[23,31–37]. 
3. Mercury-Based Working Electrodes 
Mercury has been proven to be an extremely good electrode material and has been used for a 
wide number of applications for a considerable time [38], with reports on the polarographic 
behaviour of chlordiazepoxide hydrochloride (Librium®) being made as early as 1963 by Oelschläger 
[39]. The polarographic determination of benzodiazepines offers a number of advantages, as these 
drugs are readily adsorbed at the Hg electrode surface, allowing for the highly sensitive technique of 
AdSV to be employed. 
More recently, tetrazepam has been determined at a Hg drop electrode utilising Britton-
Robinson buffer modified with 10% ethanol as the supporting electrolyte [40]. Several 
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electrochemical approaches were investigated, including differential pulse polarography (DDP), 
differential pulse cathodic adsorptive stripping voltammetry (DPAdCSV), linear sweep cathodic 
adsorptive stripping voltammetry (LSAdCSV), and square wave cathodic adsorptive stripping 
voltammetry (SWAdCSV), gaining detection limits of 5 × 10−6, 3 × 10−7, 1 × 10−8, and 3 × 10−9 M, 
respectively. Bulk, pharmaceutical formulation, and human serum were investigated, and the 
adsorptive stripping voltammetry procedures developed were shown to be able to successfully 
determine tetrazepam in human serum without any prior pre-treatment. 
Reports have shown that pharmaceuticals such as benzodiazepines are increasingly used to 
illegally fortify complementary and alternative medicines [28]. Clonazepam, flurazepam, 
alprazolam, midazolam, medazepam, chlordiazepoxide, and diazepam were successfully 
determined in phytotherapeutic formulations at a Hg drop electrode, gaining a linear range of 1.0 × 
10−6 to 30.0 × 10−6 M, utilising a pH 10 Ringer buffer solution as the supporting electrolyte. The 
benzodiazepines determined were divided into four separate groups according to their cathodic 
voltammetric behaviour, permitting the rapid voltammetric scanning of these formulations. 
The voltammetric behaviour of nitrazepam has been recently reported at dropping Hg and 
glassy carbon electrodes [41]. Voltammetric investigations utilising a pH 5.7 acetate buffer containing 
1% sodium lauryl sulphate showed two well-defined reduction peaks resulting from the 4e−, 4H+ 
reduction of the 7-nitro group to the corresponding hydroxylamine and the 2e−, 2H+ reduction of the 
azomethine group. A detection limit of 0.47 × 10−7 M was reported, and the assay was successfully 
employed for the determination of nitrazepam in tablet formulations. 
The determination of nordiazepam has been studied at the Ag–Hg amalgam electrode [42]. 
Utilising DPV with a supporting electrolyte of a pH 10 Britton-Robinson buffer and methanol (9:1), a 
linear range from 2 × 10−6 to 1 × 10−4 M with a corresponding limit a quantification of 1.7 × 10−6 M was 
reported. The Ag–Hg amalgam electrode was fabricated by immersing an Ag electrode in liquid Hg 
for 15 s. This was then electrochemically activated at a potential of −2.2 V in 0.2 M KCl. The electrode 
was periodically regenerated by switching every 0.1 s between the potentials −1.4 V and −0.8 V. 
Latterly, Nunes et al. [16] have utilised differential pulse cathodic adsorptive stripping 
voltammetry to determine the occurrence of alprazolam in Brazilian river water to evaluate its 
potential use as a marker of contamination by wastewater. Investigations showed that alprazolam 
was reduced at a HMDE giving a single irreversible reduction peak at −0.95 V in pH 7 phosphate 
buffer concluded to result from the 2e−, 2H+ reduction of the azomethine group. Peak current was 
found to increase proportionally with scan rate, demonstrating the electrochemical mechanism to be 
adsorptive in nature. Conditions were optimised for the determination of alprazolam in 
environmental water samples, and a limit of quantification of 0.4 μg/L for a 120 s pre-concentration 
time was reported with recoveries ranging from 93% to 120%. Analyses of water samples taken 
downstream of a sewage treatment works on the Cascavel River were found to have an alprazolam 
level of 5.9 ± 0.5 μg/L. 
As can be seen form Table 1, a large percentage of previous reports have utilised Hg-based 
electrodes. However, the use of Hg has fallen from favour due to problems with toxicity and 
disposability. Consequently, a number of recent reports have investigated alternative approaches, 
which are illustrated in more detail in the next section. 
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Table 1. Pre-2006 polarographic and voltammetric methods for the determination of benzodiazepines at mercury-based electrodes. 
Benzodiazepine Electrode 
Material 
Linear Range (M) Detection Limit 
(M) 
Electrolyte Waveform and 
Technique 
Sample (s) Reference 
7-acetamido-
nitrazepam, 
dimethyl-
diazepam, 
chlordiazepoxide 
lactam, 7-amino-
diazepam 
Dropping 
mercury 
electrode 
- - 
Britton-Robinson 
buffer, 0.04 M, plus 
0.1 M NaOH to obtain 
desired pH 
DPP Mechanistic study [43] 
Bromazepam, 
clonazepam, 
diazepam, 
flurazepam, 
midazolam, and 
medazepam 
Hanging 
mercury drop 
electrode 
Clonazepam 1 × 10−7 to 
1 × 10−5, bromazepam 1 
× 10−7 to 1 × 10−5, 
midazolam 1 × 10−7 to 1 
× 10−5, diazepam 1 × 10−7 
to 1 × 10−5, SWCSV 
clonazepam 1 × 10−8 to 8 
× 10−8¸ bromazepam 1 × 
10−8 to 8 × 10−8, 
midazolam 1 × 10−8 to 8 
× 10−8, diazepam 1 × 10−8 
to 8 × 10–8, medazepam 
1 × 10−8 to 8 × 10−8 
SWV, clonazepam 
1.3 × 10−8, 
bromazepam 1.2 × 
10−8, midazolam 1.6 
× 10−8, diazepam 1.0 
× 10−8, SWCSV 
clonazepam 2.9 × 
10−9, bromazepam 
2.6 × 10−9, 
midazolam 2.0 × 
10−9, diazepam 2.0 × 
10−9, medazepam 
1.3 × 10−9, 
flurazepam 2.5 × 
10−9 
0.10 M KNO3, and 
Britton–Robinson pH 
6.0 buffer 
SWV and 
SWCSV 
Tablets [44] 
Diazepam, 
oxazepam 
nitrazepam, and 
flurazepam 
Dropping 
mercury 
electrode 
2 × 10−7 to 10 × 10−7 2 × 10−7 
0.2 M acetate pH 4.8 
buffer 
DPP, DC 
polarography 
Rabbit urine [45] 
Midazolam Static mercury 
drop electrode 
3.6–36 μM 100 pM Acetate pH ca. 4.8 
buffer 
SWAdSV, NPV - [46] 
Midazolam 
Static mercury 
drop electrode 
- - 
0.1 M acetate pH 4.8 
buffer 
NPV Mechanistic study [47] 
Midazolam 
Hanging 
mercury drop 
electrode 
1.9 × 10−6 to 10−9  
Britton-Robinson pH 
5.00 buffer 
AdSV 
Pharmaceutical 
formulations 
[48] 
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Midazolam and 
metabolites (α-
hydroxy-
midazolam, 3-
hydroxy-
midazolam and 
α,3-hydroxy-
midazolam) 
Static mercury 
drop electrode 
10−4 to 10−7 6 × 10−8 Sulphuric acid 1.0 M DPP - [49] 
Camazepam and 
bromazepam 
Hanging Hg 
drop electrode 
Camazepam 1 × 10−9 to 
9 × 10−9, bromazepam 1 
× 10−8 × 10−8, 270 s at 
−0.60 V 
Camazepam 20 
ng/mL and 
bromazepam 200 
ng/mL 
 DPAdSV 
Human serum after 
isolation with Sep-
Pak CI8 cartridges 
[50] 
Flurazepam and 
metabolites 
Dropping 
mercury 
electrode 
Three orders of 
magnitude 
5 × 10−8 Formate pH 4 buffer DPP 
15 mg and 30 mg 
capsules 
[51] 
Loprazolam 
mesilate 
Static mercury 
drop electrode 
2.5 × 10−10 to 8.0 × 10−9 2.5 × 10−10 
0.04 M ammonium 
chloride pH 4.0 
SWAdCSV - [52] 
Loprazolam 
mesilate 
Dropping 
mercury 
electrode and 
a static 
mercury 
electrode 
- -  
DC, AC, normal 
and inverse 
pulse 
polarography, 
CV, and 
controlled 
potential 
coulometry 
Mechanistic study [53] 
Oxazepam and 
lorazepam 
Dropping and 
hanging 
mercury 
electrodes 
1.0 × 10−5 to 1.5 × 10−7 
for oxazepam and 2.5 × 
10−7 to 2.0 × 10−7 for 
lorazepam 
1.25 × 10−7 for 
oxazepam, 
1.85 × 10−7 for 
lorazepam 
Britton-Robinson 
buffer 
DC and AC 
polarography, 
CV, DPP, 
rotating disk 
voltammetry 
Oxazepam in 
serepax, serenal 
tablets, and serenid 
forete capsule; 
lorazepam in 
Larpose, activan, 
trapex tablets 
[54] 
Oxazepam, 
lorazepam, and 
quinazolinecarbox
aldehyde 
Dropping and 
hanging 
mercury 
electrodes 
10−5 to 10−3 in 10% 
DMSO/water, 10−5 to 
10−4 in water 
- 
0.1 M tetraethyl 
ammonium 
perchlorate in 90% 
DMSO/10% water 
polarography 
Serenid-D and 
Ativan tablets 
[55] 
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Oxazepam 
Forced drop 
mercury 
electrode 
1 × 10−5 to 1 × 10−2 - 
0.1 M aqueous 
tetraethyl ammonium 
iodide 
polarography 10 mg tablets [56] 
Halazepam 
Dropping and 
hanging 
mercury 
electrodes 
1 × 10−8 to 1.6 × 10−7 25 ng/mL 
0.04 M acetate pH 4.8 
buffer 
DPAdSV −0.5 V Human serum and 
urine 
[57] 
Bromazepam and 
N-1-
Desalkylflurazepa
m 
Dropping 
mercury 
electrode 
5–500 ng/mL 10–20 ng/mL 
1 M phosphate pH 4.0 
and pH 7.0 buffers 
containing 0.005% 
methoxypolyethylene 
glycol 550 
DPP Human blood [58] 
Flunitrazepam 
Hanging 
mercury drop 
electrode 
0.6 × 10−8 to 3.1 × 10−7 9.0 × 10−10 
0.02 M Britton-
Robinson pH 10 
buffer 
Staircase 
voltammetry 
and DPAdSV 
Urine, following 
extraction with 
diethyl ether 
[59] 
Flunitrazepam Dropping Hg 
electrode 
1.5 × 10−5 to 2.5 × 10−7 - 
0.2 M boric acid, 0.05 
M citric acid, and 0.1 
M trisodium 
orthophosphate pH 4 
buffer, containing 
0.2% Triton X-100 
DPP Rohypnol tablets [60] 
Clonazepam 
Hanging 
mercury drop 
electrode 
Up to 550 ng/mL 10 ng/mL 
0.025 M carbonate pH 
10.0 buffer 
DPAdSV 
Urine, after 
extraction 
[61] 
Nitrazepam 
Nafion-coated 
Hg film glassy 
carbon 
electrode 
Up to 7 × 10−6 - Acetate pH 4.6 buffer DPAdSV - [62] 
Nitrazepam 
Dropping 
mercury 
electrode 
- 0.27 μg/mL McIlvaine pH 3.1 
buffer 
Polarography 
Tablets: Nitravet, 
Nirven, Sedamon, 
Hypnotex, 
Restorem, and 
Capsule: Hypnotex 
[63] 
Nitrazepam 
Hanging 
mercury drop 
0.5–80 μg/mL in serum 
by polarography 
0.5 μg/mL Phosphate pH 6.9 
buffer 
Polarography, 
CV, 
chronopotentio
metry, 
Serum (without 
dilution or pre-
treatment) 
[64] 
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controlled 
coulometry 
Nitrazepam, 
flunitrazepam, 
and clonazepam 
as their 2-amino-
5-
nitrobenzophenon
es acid hydrolysis 
products 
Glassy carbon 
electrode 
- - 
Polarography, 0.11 M 
pyridine, and 0.12 M 
formic acid pH 4.5, 
CV formate buffer 
CV, 
polarography 
- [65] 
Camazepam, 
oxazepam, and 
temazepam 
Hanging 
mercury 
electrode 
Oxazepam 2.8 × 10−8 to 
4.0 × 10−7 
Oxazepam 3.6 × 10–
10 
0.008 M Britton–
Robinson pH 2.0 
buffer 
DPAdSV 
Human serum 
albumin 
[66] 
Temazepam 
Hanging 
mercury 
electrode 
10–100 μg/mL  
Acetate pH 4.7 buffer 
solution containing 
10% 
dimethylfonnamide 
Polarography 
and DPP 
Soft gelatine 
capsule 
formulations after 
enzyme dissolution 
[67] 
Pivazepam 
Hanging 
mercury 
electrode 
10−7 to 10−5 
Urine 15 ng/mL, 
following diethyl 
ether extraction 
DPAdSV 0.1 M 
McIlvaine pH 4.0 
buffer, 10% methanol, 
DPP 0.04 M Britton-
Robinson pH 5 buffer 
DPP, DPAdSV 
Pharmaceutical 
tablet formulations 
and urine 
[68] 
Chlordiazepoxide, 
nitrazepam, 
clonazepam, 
flunitrazepam, 
oxazepam, 
lorazepam, 
diazepam, 
bromazepam, 
prazepam, 
flurazepam, -
otassium 
chlorazepate, and 
medazepam 
Dropping 
mercury 
electrode 
- - 
Britton–Robinson pH 
4.0 and pH 12.0 
buffers 
Polarography 
Mechanistic studies, 
hydrolysis products 
investigated 
[69] 
chlorazepate 
Dropping Hg 
electrode 
10−7 to 3 × 10−5 ca. 10−7 
Britton-Robinson pH 
4 buffer 
Cathode ray 
polarography 
Urine after 
adjustment to pH 9 
and liquid-liquid 
[70] 
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extraction with 
ethyl acetate 
Oxazepam Dropping Hg 
electrode 
- - 
0.1 M HCl/20% 
methanol 
Polarography 
Unsuccessful for the 
direct 
determination of 
pharmaceutical 
formulation 
[71] 
Diazepam 
Dropping 
mercury 
electrode 
2 × 10−6 to 10−3 - 
Britton-Robinson pH 
1.81 buffer—0% 
methanol 
DCP, CV, 
coulometry 
Mechanism study [72] 
Diazepam 
Dropping 
mercury 
electrode 
Alternating current 
polarography 17.4–167 
μM; DPP 4.8–96 μM 
- 
2 M acetate pH 4.6 
solution 
DCP, DPP, and 
alternating 
current 
polarography 
10 mg tablets [73] 
Diazepam 
Hanging 
mercury drop 
electrode 
- 1 μg/mL 0.1 M KCl solution in 
50% ethanol 
DPP 
Forensic 
investigations of 
Toddy (fermented 
sap or exudate of 
date, Palmyra, 
coconut, sago, etc.) 
[29] 
Diazepam 
Hanging 
mercury drop 
electrode 
5.6 × 10−8 to 8.8 × 10−6 
and 8.8 × 10−6 to 2.0 × 
10−4 
9.6 × 10−9 
0.20 M pH 4.7 acetate 
buffer, −2.0 × 10−2 M 
K2S2O8 
Polarographic 
parallel catalytic 
wave of 
persulfate 
Tablets [74] 
Mexazolam 
Hanging 
mercury drop 
electrode 
Up to 13 μg/mL 80 ng/mL  DPP  [75] 
Bentazepam 
Hanging 
mercury drop 
electrode 
1.9–9.4 ng/mL by 
DPAdSV 
2.7 ng/mL in urine 
by DPAdSV; 3.1 × 
10−9 M by DPP 
DPP in 0.04 M 
Britton-Robinson pH 
9 buffer; DPAdSV in 
0.08 M phosphate pH 
8.0 buffer 
DPP, DPAdSV 
Tiadipona tablets 
by DPP and in urine 
by DPAdSV 
[76] 
Chlordiazepoxide 
Hanging 
mercury drop 
electrode 
5 × 10−9 to 2 × 10−7 in 
human serum by 
SWAdCSV 
4.4 × 10−10 and 6.6 × 
10−10 for 
pharmaceutical and 
human serum, 
respectively, by 
SWAdCSV 
Britton-Robinson pH 
8 buffer 
Polarography, 
CV, controlled 
potential 
coulometry and 
SWAdCSV 
Bulk form, Librax 
tablets and human 
serum (after protein 
precipitation with 
ethanol and 
centrifugation) 
[77] 
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Chlordiazepoxide 
Static mercury 
drop electrode 
- - 0.1 M acetate buffer SWAdCSV 
Synthetic solutions 
measured in the 
presence of 
chloramphenicol, 
metronidazole, 
oxytetracycline, 
cephalothin, and 
trimethoprim 
[78] 
Chlordiazepoxide 
Hanging 
mercury drop 
electrode 
Quasilinear over the 
ranges: 3.20 × 10−8 to 
1.60 × 10−7; 1.60 × 10−7 to 
1.44 × 10−6; 1.44 × 10−6 to 
1.44 × 10−5 
9 × 10−9 
0.12 M NH3/NH4Cl 
pH 10.2/0.016 M 
K2S2O6 
Polarography - [79] 
Chlordiazepoxide 
Hanging 
mercury drop 
electrode 
0.8 to 11 × 10−8 0.9 × 10−9 
Britton-Robinson pH 
6.8 buffer 
DPAdCSV 
Human serum, after 
solid phase 
extraction with Sep-
Pak C18 cartridge 
[80] 
Chlordiazepoxide 
Dropping Hg 
electrode 
2.5 × 10−6 to 10−3 2.5 × 10−6 0.1 M sulphuric acid 
Polarography, 
CV, coulometry 
Alpoxide and 
Prodixamon tablets, 
serum 
[81] 
Chlordiazepoxide 
and metabolites: 
N-
desmethylchlordi
azepoxide, and 
demoxepam 
Dropping Hg 
electrode 
0.05–1.0 μg/mL 
Chlordiazepoxide 
and its desmethyl 
metabolite 
approximately 0.05 
μg/mL for plasma; 
demoxepam, 0.10 
μg/mL 
0.1 N sulphuric acid DPP 
Plasma after 30 mg 
dose extracted with 
diethyl ether at pH 
9 and analytes 
isolation by thin 
layer 
chromatography 
[82] 
Chlordiazepoxide 
and diazepam 
Dropping Hg 
electrode 
- - 0.1 M sulphuric acid 
Automated 
polarography 
Alpoxide and Vival 
tablets 
[83] 
Lorazepam 
Hanging 
mercury drop 
electrode 
0.05–1.15 μg/mL 0.019 μg/mL Britton-Robinson pH 
2 buffer 
CAdSV 
Urine, plasma, 
Chemidarou and 
Zahrav tablets 
[84] 
Lorazepam 
Hanging 
mercury drop 
electrode 
 15 ng/mL in urine 
Britton-Robinson pH 
2 buffer 
DPAdSV Human urine [85] 
Nimetazepam Dropping Hg 
electrode 
30–150 μg/mL 30 μg/mL 
Britton–Robinson pH 
3.8 buffer, 50% 
methanol 
Polarography, 
0.0 to −0.7 V 
Serum and whole 
blood after 
extraction with 
[86] 
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ethyl 
acetate/toluene 1:1 
Pinazepam and 
BrTDO 
Hanging 
mercury drop 
electrode 
 
Pinazepam 2.8 × 
10−10, BrTDO 2.2 × 
10−10 
0.04 M Britton-
Robinson buffers pH 
4 and pH 5 
DPAdSV Human serum [87] 
Pinazepam, 
camazepam, 
bromazepam, and 
BrTDO 
Hanging 
mercury drop 
electrode 
Pinazepam 100–700 
ng/mL, camazepam 
100–1000 ng/mL, 
bromazepam 100–1000 
ng/mL, and BrTDO 
100–1000 ng/mL 
Pinazepam 15 
ng/mL, camazepam 
10 ng/mL, 
bromazepam 20 
ng/mL, and BrTDO 
20 ng/mL 
Britton–Robinson pH 
4 buffer for 
Pinazepam and pH 5 
for bromazepam and 
BrTDO; Acetate pH 5 
buffer for camazepam 
DPAdSV 
Urine after solid-
phase extraction 
with C18 Sep-pak 
[88] 
Timelotem 
Dropping 
mercury 
electrode 
- 2.5 × 10−6 
Britton–Robinson 
buffers containing 
10% methanol 
- - [89] 
Tetrazepam, 
nortetrazepam, 
and 
menitrazepam 
Hanging and 
dropping 
mercury 
electrodes 
5 × 10−7 to 5 × 10−6 
tetrazepam 
10−7 
0.1 M sulphuric acid, 
containing 1% 
dimethylacetamide 
Polarography 
and DPP 
- [90] 
Clotiazepam 
Dropping 
mercury 
electrode 
6.5 × 10−7 to 1.10 × 10−5 - 0.1 M sulphuric acid 
Polarography 
and DPP 
Distensan tablets [91] 
Estazolam 
Dropping 
mercury 
electrode 
1 × 10−7 to 9.0 × 10−6 5 × 10−8 
0.1 M NH3–NH4Cl pH 
9.2 buffer 
Polarography - [92] 
Camazepam 
Dropping 
mercury 
electrode 
1.3 × 10−6 to 1.0 × 10−5 by 
DPP 
1.7 × 10−8 by DPP 
0.2 M phosphate pH 
6.0 buffer 
Current 
sampled 
polarography, 
CV, and DPP 
Urine, with and 
without solid phase 
extraction (Sep-Pak 
C18) and Albego 
dragees (sugar-
coated) 10 and 20 
mg tablets 
[93] 
Metaclazepam 
DC tast, DPP 
and DPAdSV 
at dropping 
mercury, 
hanging 
mercury 
electrodes; CV 
1.8 × 10−9 to 3.2 × 10−7 by 
DPAdSV 
4.4 × 10−10 by 
DPAdSV 
Polarography: 
Britton-Robinson 
buffer; coulometry: 
4% ethanol/Britton-
Robinson buffer 
DC tast and 
DPP, CV, 
microcoulometr
y, and DPAdSV 
Human urine, 2 mL 
diluted with 1 mL 
of 0.04 M pH 9.2 
borate buffer; 
extracted with 1 mL 
of diethyl ether 
Evaporated to 
[94] 
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at hanging 
mercury 
electrode; 
coulometry at 
mercury pool 
dryness and 
reconstituted in 
ethanol; diluted 
with 25 mL 0.04 M 
Britton-Robinson 
buffer pH 9.1 
Triazolam and 
clotiazepam 
Hanging 
mercury drop 
electrode 
Up to 2.2 × 10−7 for both 
triazolam and 
clotiazepam 
6 × 10−10 for 
triazolam and 
clotiazepam with 
accumulation times 
of 4 and 10 min by 
DPAdSV 
10−2 M carbonate pH 
10 buffer 
DPAdSV - [95] 
Diazepam and 
nitrazepam 
Hanging 
mercury drop 
electrode 
1 × 10−9 to 1 × 10−6 - Acetate pH 4.6 buffer DPAdSV - [96] 
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4. Mercury Free Electrodes 
4.1. Metal Electrodes 
Channaa and Surmann [97] utilised a galinstan drop electrode as an alternative to Hg for the 
determination of chlordiazepoxide, nitrazepam, and diazepam. Galinstan is an alloy of gallium, 
indium, and tin, which is a liquid at room temperature, making it a good substitute for the potentially 
more toxic Hg. Differential pulse and adsorptive stripping voltammetry at this electrode showed very 
similar behaviour to that observed at Hg drop electrodes. In another investigation, Tyszczuk [98] 
utilised an in situ plated lead film glassy carbon electrode for the determination of temazepam and 
diazepam in tablet formulations and oxazepam in human urine. Using an electrolyte of pH 4.6 0.05 
M acetate buffer containing 5 × 10−5 M Pb, detection limits of 2.0 × 10−9, 20 × 10−9, and 5.0 × 10−9 M for 
diazepam, temazepam, and oxazepam, respectively, were obtained. 
Square wave voltammetry has been utilised to determine the adsorption of lorazepam at a gold 
ultramicroelectrode (25 μm diameter) in a 0.05 M H3PO4 [99]. A linear response was found over the 
range 10−11 to 10−6 M, with a corresponding detection limit of 6 × 10−12 M (ca. 2 pg/mL). The method 
was based on measuring changes in the admittance of a gold ultramicroelectrode (in 0.05 M H3PO4 
solution) caused by adsorption of the lorazepam of the electrode surface. The signal-to-noise ratio 
was significantly improved by application of the discrete fast Fourier transform method, background 
subtraction, and two-dimensional integration of the electrode response over a selected potential 
range and time window. The method was evaluated by determining the lorazepam content of 
commercial available tablet formulations. 
Doménech-Carbó et al. [100,101] investigated the adulteration of phytotherapeutic formulations 
with a number of different drugs, including the benzodiazepines: Clonazepam, flurazepam, 
alprazolam, midazolam, bromazepam, chlordiazepoxide, lorazepam, and diazepam. Paraffin-
impregnated graphite electrodes (PIGE) were gently rubbed in a suitable portion of the powdered 
pharmaceutical formulation under investigation. This was then rinsed with water and transferred to 
the electrochemical cell containing pH 4.75 acetate buffer as the supporting electrolyte. The physically 
adsorbed film on the electrode surface was then investigated by square wave voltammetry. The 
presence of benzodiazepine within the various formulations could then be identified by their 
different reduction peak potentials. In further studies, quantification was also shown to be possible 
using a modified multiple standard addition method [101]. 
4.2. Carbon Electrodes 
El-Sayed et al. [102] studied the electrochemical behaviour of chlordiazepoxide at both a glassy 
carbon electrode (GCE) and at a mercury drop electrode. Under acidic conditions, three irreversible 
reduction waves were reported, corresponding to three separate twoelectron reduction steps. Cyclic 
voltammetric investigations over the potential range 0.0 to −1.2 V showed two reduction peaks, with 
no oxidation peaks seen on the return positive going scan. The cathodic adsorptive stripping 
voltammetric behaviour of chlordiazepoxide was studied at the GCE. Using a linear-sweep 
waveform for quantitative determination of chlordiazepoxide in serum and commercial tablets by 
dilution in pH 4 Britton-Robinson buffer, a linear relationship between peak current and drug 
concentration was obtained over the range 2 × 10−7 to 5 × 10−6 M, with a corresponding detection limit 
of 5 × 10−8 M. Utilising a relatively simple sample preparation via dilution with buffer, recoveries 
ranging between 97 and 102.5% were reported for both sample types. 
Recently [103], the voltammetric behaviour of bromazepam and alprazolam were investigated 
at both laboratory-fabricated and commercially available unmodified and Hg-free boron-doped 
diamond electrodes (BDDE). Cyclic voltammetric investigations were reported to show that both 
bromazepam and alprazolam underwent an irreversible and diffusion-controlled reduction process 
at these electrodes. Bromazepam was reported to give a single reduction peak at −1.10 V in a pH 11 
Britton-Robinson buffer for both the commercial and laboratory-fabricated electrodes. Alprazolam 
was reported to give a single peak, with a peak potential of −0.84 V in a pH 5 Britton-Robinson buffer 
of pH 5 at the commercial BDDE. Using differential pulse voltammetry, linear calibration curves were 
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obtained for bromazepam and alprazolam from 1 × 10−6 to 1 × 10−4 and 8 × 10−7 to 1 × 10−4 M, with 
detection limits of 3.1 × 10−7 and 6.4 × 10−7 M, respectively. Using the optimised conditions, 
investigations of pharmaceutical tablets were reported to give mean recoveries of 97.3% to 100.9% for 
bromazepam and from 94.1% to 101.3% for alprazolam. 
The five benzodiazepines—clonazepam, diazepam, alprazolam, chlordiazepoxide, and 
oxazepam—have been determined at a poly dopamine-poly folic acid (PDA–FA) nanocomposite-
modified GCE [104]. Investigations using cyclic voltammetry were reported to show that the 
modified GCE exhibited enhanced voltammetric responses for the oxidation of these five 
benzodiazepines in alkaline solutions. The authors investigated the possibility of determining the 
benzodiazepines by DPV. The method was successfully applied for the determination of the drugs in 
human plasma samples. Recoveries were reported to range between 92.5% and 110%. Following 
polishing with 0.05 μm alumina, a dopamine/folic acid film was electrochemically polymerised on 
the GCE surface. This was achieved by repeated cyclic voltammetric scanning over the range −1.0 to 
+1.0 V, at a scan rate of 100 mV/s in a 0.1 M phosphate saline pH 7.4 buffer containing 0.5 mg/mL 
dopamine. Once 15 cyclic voltammetric cycles were completed, the dopamine peak currents were 
reported to become constant. The modified GCE was then transferred to a separate 1 mM HCl 
solution containing 0.9 mM folic acid, and repeated cyclic voltammetric scanning over the potential 
range −1.0 to +1.5 V at a scan rate of 50 mV/s for 10 cycles. 
4.3. Graphene-Modified Electrodes 
Chlordiazepoxide has also been investigated by Motaharian and Hosseini [105] at a grapheme-
carbon paste electrode (GCPE) modified with imprinted polymer nanoparticles (nano-MIP). 
Chlordiazepoxide imprinted polymer nanoparticles were prepared by a suspension polymerisation 
method from methacrylic acid (functional monomer), ethylene glycol dimethacrylate (cross-linker), 
and 2,2-azobisisobutyronitrile (initiator) in acetonitrile. This pre-polymerisation mixture was added 
to the 60 mL of nitrogen-purged silicon oil and dispersed by stirring and ultrasonication. After 
heating to complete polymerisation, the polymer particles were filtered and washed with petroleum 
ether and toluene. The chlordiazepoxide and un-polymerised components were then removed by 
washing with methanol/acetic acid and ethanol and dried. Modified carbon paste electrodes were 
prepared from graphite powder, graphene, MIP modifier, and n-eicosane. This was then packed into 
the end of a glass holder and an electrical connection made with a copper wire. The modified 
electrode was incubated in a CDP solution (pH 3.5) for 10 min with stirring, and then washed and 
placed in an electrochemical cell containing 10 mL of a 0.1 M sulphuric acid solution, and the 
concentration of chlordiazepoxide determined by square wave voltammetry. The nano-MIP-
modified electrodes exhibited much greater adsorption towards chlordiazepoxide than the non-
imprinted polymer nanoparticle. They also showed that the inclusion of graphene in the preparation 
of the carbon paste electrode gave a significant improvement in response. A linear range from 6.0 × 
10−10 to 7.5 × 10−8 M (R2 = 0.9982) was reported with an associated detection limit of 2.61 × 10−10 M. The 
determination of chlordiazepoxide in pharmaceutical formulations, human serum, and urine 
samples was shown possible, with mean recoveries of 99.0%, 94.5%, and 97.8%, respectively, 
reported. 
Rezaei et al. [106] determined lorazepam at a pencil graphite electrode (PGE) modified with an 
electro-polymerised molecularly imprinted polymer (MIP) formed from polypyrrole (ppy), sol-gel 
modified with Au nanoparticles (AuNPs). The surface of the PGE was first pre-treated by applying a 
constant potential of +1.40 V for 300 s in a 0.5 M pH 4.8 acetate buffer supporting electrolyte, 
containing 0.02 M NaCl. The pre-treated electrode was immersed in a sol formed from 
tetraethoxysilane (TEOS), phenyltriethoxysilane (PTEOS), trifluoroacetic acid (TFA), ethanol, 
lorazepam, pyrrole, sodium dodecyl sulfate (SDS), and hydrogen tetrachloroaurate trihydrate 
(HAuCl4 3H2O). The potential of the PGE was then scanned over the range of −0.80 to +0.60 V (vs. 
Ag/AgCl) by cyclic voltammetry (50 mV/s for 7 cycles) to give a polypyrrole@sol-gel@Au 
nanoparticle MIP film. Lorazepam was extracted from the MIP film by immersion in a methanol-
acetic acid (50% v/v) solution. The fabrication process of the sensor was characterised by cyclic 
Biosensors 2019, 9, 130 14 of 33 
voltammetry and electrochemical impedance spectroscopy (EIS). Under the optimised conditions, 
linear responses from 0.2 to 2.0 nM and 2.0 to 20.0 nM were reported, with a detection limit of 0.09 
nM. The possibility of utilising the developed sensor for the determination of lorazepam in tablet 
formulations, plasma, and urine was investigated and mean recoveries of 102% were reported for all 
three sample types. Panahia et al. [107] utilised the alternative precipitation polymerisation method 
to modify the surface of a carbon paste electrode with a MIP for the determination of midazolam. 
Linear responses of 5.0 × 10−10 to 1.0 × 10−7 M and 1.0 × 10−7 to 1.0 × 10−6 M were reported, with 
corresponding detection limits of 1.77 × 10−10 M. The sensor was successfully used to determine 
midazolam concentrations in pharmaceutical formulations and human urine, gaining reported mean 
recoveries of 101.5% and 93.1%, respectively. 
Ag–Pt core–shell nanoparticles supported on graphene nano-sheets (Ag–Pt/GRs/GCE) have 
been used to fabricate a sensor for oxazepam [108]. These were shown to be able to successfully 
determine of oxazepam in serum, urine, and pharmaceutical preparations. Voltammetric 
investigations showed a reportedly significant enhancement of the reduction current, and also a 
reduction in overvoltage required. Ag–Pt/GRs were prepared by mixing H3PO4/H2SO4 and 
graphite/KMnO4 at 60 °C 15 h before the addition of 30% H2O2. Following centrifugation, and 
filtration, the graphene oxide was washed with water, 30% HCl, and finally ethanol. The GO powder 
was ultrasonically dispersed in aqueous AgNO3 stabilised with sodium citrate solution. After the 
addition of sodium borohydride aqueous solution, the product was collected by centrifugation and 
dispersed into an ethylene glycol/water and finally filtrated, washing with water and dried. The GCE 
was then modified by drop-coating the silver–platinum core–shell nanoparticles supported and 
graphene and drying at room temperature. The electrochemical parameters were optimised, and a 
linear range of 0.05–150.0 μM (R = 0.9997) and a detection limit of 42 ± 1 nM for oxazepam by 
differential pulse voltammetry was reported. Analysis of oxazepam over the concentration range 5 
to 120 μM in urine and human blood serum gave reported recoveries of 99.9% and 102%, respectively. 
Using the developed device, oxazepam tablets were reported to contain 94 mg/tablet, within 6% of 
the stated value. 
4.4. Nanoparticles, Carbon Nanotubes, and Fullerene-Modified Electrodes 
The reported synergic effect of Au nanoparticles and graphene has been investigated for the 
possible voltammetric determination of nitrazepam [109]. Using differential pulse voltammetry, a 
linear range of 0.5 to 400 μM with a corresponding detection limit of 0.166 μM was reported. 
Recoveries of between 99% to 102.4% were reported for serum and a pharmaceutical formulation. 
The modified electrode was fabricated by first drop casting an aqueous suspension of reduced 
graphene oxide onto a GCE. This was then immersed in an acetate buffer solution containing 1 mM 
HAuCl4. Au nanoparticles were then deposited from this solution onto the modified GCE surface via 
repeated cyclic voltammetric scanning over the potential range −0.2 V to +1.2 V (vs. Ag/AgCl), at a 
scan rate of 100 mV/s. The Au nanoparticle/graphene nanostructure was characterised by Fourier 
transform infrared spectroscopy, atomic force microscopy, scanning electron microscopy coupled 
with energy dispersive X-ray spectroscopy, and voltammetry. 
Recently, Rahimi-Nasrabadi et al. [110] explored the possibility of determining diazepam in 
serum, urine, and tablets at a fullerene-functionalised carbon nanotubes/ionic liquid nanocomposite-
modified GCE. The electrode was modified using fullerene-functionalised carbon nanotubes and 
ionic liquid (1-butyl-3-methylimidazolium tetrafluoroborate). The properties of fullerene-
functionalised carbon nanotubes and ionic liquid were characterised by transmission electron 
microscopy, scanning electron microscope, electrochemical impedance spectroscopy, and 
voltammetry. It was reported that the modified GCE showed electrocatalytic activity toward the 
reduction of diazepam and a linear response over the range 0.3–700 μM, with an associated detection 
limit of 87 ± 2 nM being obtainable. Mean recoveries of 100% and 101% were reported for urine and 
serum, respectively. 
The possibility of determining clonazepam has been investigated at a poly melamine and 
multiwalled carbon nanotubes nanocomposite (PMela/CNTs)-modified GCE [111]. The GCE was 
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modified by first drop casting an aqueous suspension of MWCNTs on to its surface. An 
electrochemically-polymerised layer of polymelamine was then added by cyclic voltammetric 
scanning over the potential range +0.1 to +1.8 V for 15 cycles at a scan rate of 100 mV/s in a 0.1M HCl 
solution containing 1.0 mM melamine. Following a 100 s accumulation time, a weak and broad peak 
was observed at −0.72 V at the unmodified GCE surface, whereas a well-defined and distinct cathodic 
peak was reported for clonazepam at −0.58 V at the PMela/CNTs/GCE. The peak current for this peak 
was reported to be ca. 15 times greater than that reported for the peak current at the bare GCE. This 
increased adsorption was reported to be a result of the interaction between clonazepam and 
polymelamine/MWCNTs and the π–π interaction between the aromatic ring of clonazepam and the 
structure and the benzene rings of MWCNTs. Employing the optimised conditions, a linear square 
wave voltammetric response was reported over the range 0.05 to 10 μM, with a detection limit of 63 
nM (3 σ). 
Ashrafia et al. [112] have reported the development of an ink based on Ag nanoparticle–
nitrogen-doped graphene quantum dots (Ag/N-GQD) for the determination of alprazolam, 
chlordiazepoxide, diazepam, oxazepam, and clonazepam in pharmaceutical and human plasma 
samples. The polymeric conductive film was electrodeposited on the surface of the poly chitosan-
modified Au electrode. Both DPV and SWV were explored for the determination of the five 
benzodiazepines. By DPV, the limit of quantification (LOQ) for alprazolam and chlordiazepoxide 
was reported as 56 μM and 52 μM, respectively, compared to 73 μM and 70.4 μM by SWV. However, 
DPV was less sensitive for clonazepam with a LOQ of 84 μM compared to 54 μM by SWV. Using a 
0.1 M NaOH supporting electrolyte, it was reported possible to determine the drugs in diluted human 
plasma. 
4.5. Screen-Printed Electrodes 
As can be seen from the preceding section, the majority of voltammetric assays utilise the 2e−, 
2H+ reduction of the 4,5-azomethine bond; however, in the case of species such as nitrazepam, the 
reduction of the nitro group can be utilised as the analytical signal [34,35,103,113]. However, these 
approaches can suffer from some certain drawbacks, as the simultaneous reduction of oxygen present 
in the sample can result in interfering reduction waves. McGuire et al. [114] recently utilised an 
alternative approach for the adsorptive anodic stripping voltammetric determination of nitrazepam 
in beverage samples at a screen-printed carbon electrode (SPCE). Cyclic voltammetric investigations 
showed the 7-nitro group to be reduced to the corresponding hydroxylamine (Scheme 1). A second 
reduction peak was recorded at more negative potentials resulting from the 2e−, 2H+ reduction of the 
4,5-azomethine group. Once generated, the hydroxylamine can be re-oxidised to the nitroso species 
at potential close to 0 volts. The use of this oxidation process as the analytical signal has several 
advantages, as many common electrochemical interferences are not seen at such low applied 
potentials. 
More recently, Honeychurch et al. [115] described the development of a voltammetric method 
based on a SPCE for the determination of clonazepam in serum and in wine. They first explored the 
cyclic voltammetric behaviour of clonazepam and the effects of pH and scan rate on the peak current 
and peak potential of the two reduction peaks and oxidation peaks. The two reduction peaks were 
recorded on the initial negative going scan, and were considered to be consistent with the 2e−, 2H+ 
reduction of the 4,5-azomethine and the 4e−, 4H+ reduction of the 7-NO2 to a hydroxylamine. On the 
return positive going scan, an oxidation peak was seen, postulated to result from the 2e−, 2H+ 
oxidation (O1) of the hydroxylamine to the corresponding nitroso species, similar to that given in 
Scheme 1 for nitrazepam. Consistent with a number of other benzodiazepines, at pH 11, the solution 
of clonazepam was found to turn from clear to a yellow colour. Gas chromatography/mass 
spectrometry (GC/MS) (Figure 1a) was used to investigate the possible reason for this colour 
formation. Following solvent extraction GC/MS results showed the presence of a compound 
tentatively identified as the base hydrolysis product of clonazepam (Figure 1b), and a smaller amount 
of clonazepam (Figure 1c). The resulting cyclic voltammetric peak current (Figure 1d) for this product 
was found to be directly proportional to scan rate, indicative of adsorption. This adsorption 
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phenomena was exploited to development an adsorptive stripping voltammetric assay for the drug. 
Using this approach, the experimental conditions required for the differential pulse adsorptive 
voltammetric measurement of clonazepam in wine and serum samples were optimised. It was 
reported that this could be performed on sample volumes as small as 100 μL deposited on the SPCE 
surface. Mean recoveries of 79.53% (%CV = 9.88%) and 88.22% (%CV = 14.1%) were reported for wine 
fortified with 3.16 μg/mL and serum fortified with 12.6 μg/mL, respectively. 
 
 
Scheme 1. Proposed voltammetric redox behavior of nitrazepam at a screen-printed carbon electrode. 
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Figure 1. Gas chromatography of clonazepam and possible base hydrolysis product. (a) Full scan 
chromatogram; (b) hydrolysis mass spectrum (retention time 24.1 min); (c) clonazepam mass 
spectrum (retention time 26.2 min); and (d) cyclic voltammogram obtained in pH 11 phosphate buffer 
for a 1 mM clonazepam solution [116]. 
As a result of the association of flunitrazepam (Rohypnol) with drug-facilitated sexual assault, 
there has been increasing interest in the development of methods capable of determining in beverages 
at the point of need. Recently [117], Tseliou et al. reported an SPCE-based sensor for the 
determination of flunitrazepam in untreated, undiluted alcoholic and soft drinks. The sensor is based 
on modification of the surface of the SPCE via electrical discharge. This was undertaken by inducing 
multiple electrical sparks from an Fe wire connected to a 1.2 kV transformer across the surface of the 
SPCE. The SPCE was brought into close proximity (<1 mm) with the Fe wire as cathode (−) and the 
SPCE as the anode (+). The SPCE was then further modified drop coating a solution of glucose oxidase 
(GOx) and glucose hydrogel droplets (GluHD) in pH 7 phosphate buffer. Investigations showed the 
iron spark-treated SPCE to be ca. three times more sensitive towards flunitrazepam compared to the 
untreated SPCE. Interferences from dissolved oxygen were removed via its reduction in the 
enzymatic oxidation of GluHD by GOx. This allowed for the voltammetric determination of the 
reduction of the nitro group of flunitrazepam to be successfully measured unperturbed by the 
potentially interfering oxygen reduction processes. The detection of flunitrazepam in fortified and 
unfortified samples of Pepsi Cola®, vodka, whisky, tequila, gin, and rum were investigated and the 
Biosensors 2019, 9, 130 18 of 33 
sensor was reported to hold promise as an effective method for the determination of flunitrazepam 
in such samples. 
Garcia-Gutierrez and Lledo-Fernandez [118] utilised an Hg-free SPCE for the voltammetric 
determination of flunitrazepam (Rohypnol) and 7-amino flunitrazepam in oral fluid, urine, and 
alcoholic beverages. Cyclic voltammetric investigations demonstrated that flunitrazepam exhibited 
similar voltammetry behaviour to that shown to nitrazepam described above. However, the authors 
reported an alternative voltammetric mechanism. Here, the 7-nitro of flunitrazepam was reported to 
be reduced via 6e−, 6H+ to the corresponding 7-amino group (Equation (1)). This was oxidised on the 
return positive going scan to the hydroxylamine at −0.2 V, forming a quasi-reversible pair (Equation 
(2)). Cyclic voltammetric peak current responses obtained in a pH 6 phosphate buffer solution 
showed a linear relationship for the oxidation peak obtained at −0.2 V over the concentration range 
1.0 to 100 μg/mL. 
R-NO2 + 6e− + 6H+ → R-NH2 + 2H2O (1) 
R-NH2 + H2O ↔ R-N(H)OH + 2e− + 2H+ (2) 
The validity of the proposed cyclic voltammetric mechanism was further investigated by 
undertaking cyclic voltammetric studies on 7-amino-flunitrazepam. The same quasi-reversible pair 
was obtained, concluded to demonstrate the formation of 7-amino-flunitrazepam to be responsible 
for the reversible redox pair. The possibility of determining flunitrazepam by cyclic voltammetry in 
oral fluid, urine, and alcoholic beverages was investigated. The lowest concentration of 
flunitrazepam that could be detected using cyclic voltammetry was found to correspond to ~30 
μg/mL. Chronoamperometry was explored to determine lower levels of flunitrazepam. Using the 
chronoamperometry response obtained at −0.1 V after 40 s, a linear response was observed over the 
range 35 to 1100 ng/mL, with a corresponding detection limit of 30 ng/mL (based on 3 σ). 
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Table 2. Pre-2006 voltammetric methods for the determination of benzodiazepines at carbon-based electrodes. 
Benzodiazepine Electrode 
Material 
Linear Range (M) Detection 
Limit (M) 
Electrolyte Waveform and 
Technique 
Sample (s) Reference 
Diazepam, 
temazepam, and 
oxazepam 
Modified 
carbon-paste 
electrodes 
Diazepam 0.025–3.0 
μg/mL, Temazepam 
0.025–0.8 μg/mL, 
oxazepam 0.025–1.0 
μg/mL 
Diazepam 
0.021 μg/mL, 
temazepam 
0.021 μg/mL, 
oxazepam 
0.012 μg/mL 
Britton-Robinson 
buffer 0.1 M 
DPV 
Plasma and urine, 
following SPE 
[119] 
Loprazolam 
Carbon-paste 
electrode 
 1.5 × 10−7 
Britton-Robinson pH 
6.3 buffer 
DPV 
Somnovit (1 mg) 
tablets 
[120] 
Flunitrazepam 
Bentonite-
modified 
carbon paste 
0.2–4.0 μg/mL 0.04 μg/mL 
Accumulation media: 
pH 3.8, adjusted with 
either nitric acid or 
potassium hydroxide; 
measurement media: 
0.5 M potassium 
nitrate pH 3.8 
DPV, adsorption 
at open circuit 
Serum and urine [121] 
Olanzapine 
Glassy carbon 
electrode 
6.2–50.0 μg/mL 3 μg/mL 0.25 M phosphate pH 
2.5 buffer 
LSV Ziprexa tablets [122] 
Bentazepam 
C18(Bonda 
pack, 50% 
w/w)-modified 
carbon-paste 
electrode 
0.5–2 μg/mL 0.5 μg/mL 
Accumulation media: 
0.04 M Britton-
Robinson pH 6 
buffer; measurement: 
0.3 M phosphate pH 2 
buffer 
DPAdSV, open 
circuit 
accumulation, 
measurement 
DPV scan 0 to +1.3 
V 
Human urine [123] 
Olanzapine 
Glassy carbon 
electrode 
DPV and OSWV 7.00 × 
10−5 to 1.00 × 10−3 
DPV 6.79 × 
10−6, OSWV 
6.91 × 10−6 
Britton-Robinson pH 
3.24 buffer 
CV, DPV, and 
OSWV 
10 mg Zyprexa 
tablets 
[124] 
Nitrazepam and 
flunitrazepam 
Glassy carbon 
electrode 
5.6–28.1 pg/mL and 6.3–
31.3 pg/mL for 
nitrazepam and 
flunitrazepam, 
respectively 
1.8 μg/mL 
and 1.3 
μg/mL for 
nitrazepam 
and 
flunitrazepa
m, 
respectively 
0.1 M phosphate pH 
7.0 buffer, containing 
10% v/v methanol 
Flow injection 
analysis, 4.0 
mL/min, −0.9 V 
Tablet 
formulations of 
nitrazepam and 
flunitrazepam 
[125] 
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Clonazepam 
Glassy carbon 
electrode 
6.3–31.5 pg/mL 3.3 μg/mL 
0.1 M phosphate 
buffer solution (pH 
7.0) containing 10% 
v/v methanol 
Flow injection 
analysis, 4.0 
mL/min, −0.9 V 
Tablet 
formulations and 
human urine 
[126] 
Diazepam 
Glassy carbon 
electrode 
1 × 10−3 to 1 × 10−4 - 
HCl–KCl pH 1 buffer 
containing 10% 
ethanol 
CV 
Tablets, capsules, 
injection, and 
syrup 
formulations 
[127] 
Diazepam 
Glassy carbon 
electrode 
0.158–9.48 μM - 
Solution of 0.1 M KCl 
and 0.01 M pH 4.0 
potassium 
biphthalate buffer 
Pulsed rotation 
voltammetry 
- [128] 
Chlordiazepoxide, 
medazepam, 
nitrazepam, amino-
nitrazepam, 
lorazepam, and 
flurazepam 
Glassy carbon 
electrode 
- - 
Britton–Robinson pH 
4 buffer, containing 
10% methanol 
Differential pulse 
flow injection 
analysis +1.2 V 
(no oxidation 
signal seen for 
nitrazepam) 
Tablets [129] 
Tifluadom 
C18 
μBondapak-
modified 
carbon-paste 
electrode 
2.2 × 10−7 to 4.5 × 10−6 
1.3 × 10−6 in 
urine, 1.3 × 
10−7 in buffer 
Britton-Robinson pH 
6 buffer 
CV Urine [130] 
Alprazolam 
Glassy carbon 
electrode and 
static Hg drop 
electrode 
2.5 × 10−7 to 3.25 × 10−5 - 
Britton-Robinson pH 
9 buffer 
Differential pulse 
polarography 
- [131] 
Flurazepam, 
oxazepam, 
medazepam, 
lorazepam, 
flunitrazepam, 
prazepam, potassium 
chlorazepate, 
nitrazepam, and 
amino-nitrazepam 
Wall-jet glassy 
carbon 
electrode 
- - 
Britton-Robinson pH 
4 buffer, containing 
10% methanol 
Differential pulse 
flow injection 
analysis +1.2 V 
Tablets [132] 
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Flurazepam, 
chlordiazepoxide, 
oxazepam, lorazepam, 
potassium 
chlorazepate, 
nitrazepam, 
flunitrazepam, 
prazepam, diazepamm 
and medazepam, and 
some of their 
metabolites 
Wall-jet glassy 
carbon 
electrode 
5 × 10−5 to 2 × 10−4 - 
0.01 M sodium 
hydroxide 
Differential pulse 
flow injection 
analysis +1.2 V 
- [133] 
Quetiapine fumarate 
and olanzapine 
Glassy carbon 
electrode 
Quetiapine 3 × 10−8 to 4 × 
10−6, and quetiapine 
fumarate 2 × 10−8 to 5 × 
10−6 
1 × 10−8 for 
both 
Britton-Robinson pH 
2 buffer 
Differential pulse 
voltammetry 
Tablets (Zyprexa 
and Seroquel), 
urine, and serum 
[134] 
Note: Cathodic adsorptive stripping voltammetry (CAdSV), differential pulse adsorptive stripping voltammetry (DPAdSV), differential pulse polarography (DPP), 
square wave adsorptive stripping voltammetry (SWAdSV), normal pulse voltammetry (NPV), linear sweep voltammetry (LSV), Osteryoung square wave 
voltammetry (OSWV), cyclic voltammetry (CV), and linear sweep voltammetry (LSV). 
Table 3. Ion-selective electrodes for the determination of benzodiazepines. 
Benzodiazepine Electrode Material Linear Range (M) 
Detection Limit 
(M) Electrolyte  Sample (s) Reference
 
Diazepam, bromazepam, 
and clonazepam 
PVC-based ion-
selective 
electrodes 
2.5 × 10−6 to 10−4, 5 × 
10−6 to 10−4, and  2.5 × 
10−4 to 10−6 for 
diazepam, 
bromazepam, and 
clonazepam, 
respectively 
2, 0.307, and 0.9 μM, 
for diazepam, 
bromazepam, and 
clonazepam, 
respectively 
Potentiometric, 
10−4 M HCl 
Ion-selective 
electrodes 
Urine, Vallium, 
Rivotril, and 
Calmepam tablets 
[135] 
Bromazepam 
Bromazepam-
phosphotungest
iate ion 
association 
complex in 
poly(vinyl 
chloride) 
membrane 
1 × 10−2 to 1 × 10−4 3 × 10−5 Potentiometric 
Ion-selective 
electrodes 
Lextonil, Neoopt, 
and Calmepam 
tablets 
[136] 
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Diazepam, bromazepam, 
and clonazepam 
PVC solid 
contact ion-
selective 
electrodes 
0.29–71.20, 0.79–31.62, 
and 0.32–31.57 μg/mL 
for diazepam, 
bromazepam, and 
clonazepam, 
respectively 
0.71, 0.79, and 0.79 
μg/mL for 
diazepam, 
bromazepam, and 
clonazepam, 
respectively 
Potentiometric, 
10−4 M HCL 
Ion-selective 
electrodes 
Vallium, Rivotril, 
and Calmepam 
tablets 
[137] 
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5. Ion Selective Electrodes 
Ion-selective electrodes offer a number of advantages, including cost and simplicity. Only a 
small number of reports have been focused on their application for the determination of 
benzodiazepines, as summarised in Table 3. Salem et al. [135,137] proposed an ion-selective electrode 
for the determination of diazepam, bromazepam, and clonazepam in tablets and in biological fluids. 
The electrodes were based on poly(vinyl chloride) or poly(esterurethane)s membranes, doped with 
drug–tetraphenyl borate or drug–phosphotungstic acid ion pair complexes as electroactive materials. 
Al Attas et al. [136] developed an ion-selective electrode for the determination of bromazepam 
based on the bromazepam–phosphotungestiate ion-association complex as an electroactive material 
in poly(vinyl chloride) membrane plasticised with o-nitrophenyloctyl ether and dioctyl sebacate. In 
aqueous solution of pH 3, the sensor was reported to be stable for 4 weeks, giving reproducible 
potential and linear responses. 
6. Conclusions 
The benzodiazepine class of drugs have been used pharmaceutically since the early 1960s, and 
is still commonly used medically for a wide number of conditions. Reports have shown that their use 
in criminal activity and their contamination of the environment have become now more commonly 
reported problems. Consequently, there is a pressing need for techniques capable of routine 
monitoring of trace concentrations in a variety of samples. Benzodiazepines are characterised by a 
relatively easily electrochemically reducible azomethine group, with a number also characterised by 
groups such as nitro, hydroxyl, and N-oxide, making them readily detectable by commonly utilised 
electrochemical methods and at a range of different electrode materials. A large proportion of the 
earlier reported research has focused on the use of Hg-based electrodes, characterised by low 
detection limits in both biological and pharmaceutical samples, requiring little sample preparation. 
However, in the proceeding five years, reports utilising these electrodes have greatly decreased, 
probably as a result of changing legislation and attitudes to the toxic effects of this element; 
nevertheless, methods based on Hg electrodes are still reported. 
Applications for the liquid chromatographic electrochemical determination of 
1,4-benzodiazeapines have utilised both reductive and, more recently, dual electrode modes of 
detection. Both approaches have been shown to be selective, sensitive, and capable of determining 
benzodiazepines in complex samples, such as serum and forensic samples. However, the reductive 
mode has been shown to suffer from common interferences, such as oxygen. 
It is believe that in the future, new analytical developments will continue to be made for other 
areas other than medical and pharmaceutical analysis, such as in forensic and environmental analysis 
and has already been shown for the simulation of drug metabolism. The development of new 
benzodiazepines and applications will also drive the further development of electrochemical assays 
for this important class of drugs. 
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Appendix A 
Structures of benzodiazepines and related compounds studied in this review. 
  
Alprazolam Bentazepam 
  
Bromazepam BrTDO 
  
Camazepam Chlordiazepoxide 
  
Clonazepam Clotiazepam 
N
N
H
OHCl
  
Demoxepam Diazepam 
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Estazolam Flunitrazepam 
 
 
Flurazepam Halazepam 
 
 
Loprazolam Lorazepam 
  
Medazepam Metaclazepam 
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N
N
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Cl
O
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Mexazolam Midazolam 
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N
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Cl
CH3SO3H
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N
O2N
O
  
Nimetazepam Nitrazepam 
  
Olanzapine Oxazepam 
N
N
Cl
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Pinazepam Pivazepam 
 
 
Potassium chlorazepate Prazepam 
  
Quinazolinecarboxaldehyde R = Cl or H Temazepam 
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